Cargando…
How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome
The treatment goals for glaucoma are lowering the intraocular pressure and preservation of vision. Topical hypotensive drops are the standard form of therapy which is often associated with some symptoms of toxicity, ocular inflammation, allergy, or ocular surface disease (OSD). OSD is a common comor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809958/ https://www.ncbi.nlm.nih.gov/pubmed/24224176 http://dx.doi.org/10.1155/2013/696328 |
_version_ | 1782288733310025728 |
---|---|
author | Kaštelan, Snježana Tomić, Martina Metež Soldo, Kata Salopek-Rabatić, Jasminka |
author_facet | Kaštelan, Snježana Tomić, Martina Metež Soldo, Kata Salopek-Rabatić, Jasminka |
author_sort | Kaštelan, Snježana |
collection | PubMed |
description | The treatment goals for glaucoma are lowering the intraocular pressure and preservation of vision. Topical hypotensive drops are the standard form of therapy which is often associated with some symptoms of toxicity, ocular inflammation, allergy, or ocular surface disease (OSD). OSD is a common comorbidity in glaucoma patients, and its prevalence with glaucoma increases with age. Use of topical treatment could additionally increase symptoms of OSD mostly due to preservatives added to multidose medication bottles used to reduce the risk of microbial contamination. This toxicity has been particularly associated with BAK, the most commonly used preservative which damages conjunctival and corneal epithelial cells and significantly aggravates OSD symptoms. OSD adversely affects patients' quality of life causing discomfort and problems with vision which in turn may result in noncompliance, lack of adherence, and eventually visual impairment. In the management of glaucoma patients OSD symptoms should not be overlooked. If they are present, topical glaucoma treatment should be adapted by decreasing the amount of drops instilled daily, using BAK-free or preservative-free medication and lubricants if necessary. Awareness of the presence and importance of OSD will in turn improve patients' adherence and compliance and thus ultimately the preservation of long-term vision. |
format | Online Article Text |
id | pubmed-3809958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38099582013-11-10 How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome Kaštelan, Snježana Tomić, Martina Metež Soldo, Kata Salopek-Rabatić, Jasminka Biomed Res Int Review Article The treatment goals for glaucoma are lowering the intraocular pressure and preservation of vision. Topical hypotensive drops are the standard form of therapy which is often associated with some symptoms of toxicity, ocular inflammation, allergy, or ocular surface disease (OSD). OSD is a common comorbidity in glaucoma patients, and its prevalence with glaucoma increases with age. Use of topical treatment could additionally increase symptoms of OSD mostly due to preservatives added to multidose medication bottles used to reduce the risk of microbial contamination. This toxicity has been particularly associated with BAK, the most commonly used preservative which damages conjunctival and corneal epithelial cells and significantly aggravates OSD symptoms. OSD adversely affects patients' quality of life causing discomfort and problems with vision which in turn may result in noncompliance, lack of adherence, and eventually visual impairment. In the management of glaucoma patients OSD symptoms should not be overlooked. If they are present, topical glaucoma treatment should be adapted by decreasing the amount of drops instilled daily, using BAK-free or preservative-free medication and lubricants if necessary. Awareness of the presence and importance of OSD will in turn improve patients' adherence and compliance and thus ultimately the preservation of long-term vision. Hindawi Publishing Corporation 2013 2013-10-09 /pmc/articles/PMC3809958/ /pubmed/24224176 http://dx.doi.org/10.1155/2013/696328 Text en Copyright © 2013 Snježana Kaštelan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kaštelan, Snježana Tomić, Martina Metež Soldo, Kata Salopek-Rabatić, Jasminka How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title | How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title_full | How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title_fullStr | How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title_full_unstemmed | How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title_short | How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome |
title_sort | how ocular surface disease impacts the glaucoma treatment outcome |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809958/ https://www.ncbi.nlm.nih.gov/pubmed/24224176 http://dx.doi.org/10.1155/2013/696328 |
work_keys_str_mv | AT kastelansnjezana howocularsurfacediseaseimpactstheglaucomatreatmentoutcome AT tomicmartina howocularsurfacediseaseimpactstheglaucomatreatmentoutcome AT metezsoldokata howocularsurfacediseaseimpactstheglaucomatreatmentoutcome AT salopekrabaticjasminka howocularsurfacediseaseimpactstheglaucomatreatmentoutcome |